Literature DB >> 19138950

Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops.

Adi F Gazdar1, John D Minna.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 19138950      PMCID： PMC2849648          DOI： 10.1158/1940-6207.CAPR-08-0080

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN： 1940-6215


× No keyword cloud information.
  37 in total

Review 1.  Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic.

Authors:  John Mendelsohn
Journal:  Cancer Immunol Immunother       Date:  2003-03-14       Impact factor: 6.968

Review 2.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

Review 3.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

4.  Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements.

Authors:  L Frederick; G Eley; X Y Wang; C D James
Journal:  Neuro Oncol       Date:  2000-07       Impact factor: 12.300

5.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.

Authors:  Ximing Tang; Hisayuki Shigematsu; B Nebiyou Bekele; Jack A Roth; John D Minna; Waun Ki Hong; Adi F Gazdar; Ignacio I Wistuba
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

6.  High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

Authors:  Nobukazu Fujimoto; Marie Wislez; Jie Zhang; Kentaro Iwanaga; Jennifer Dackor; Amy E Hanna; Shailaja Kalyankrishna; Dianna D Cody; Roger E Price; Mitsuo Sato; Jerry W Shay; John D Minna; Michael Peyton; Ximing Tang; Erminia Massarelli; Roy Herbst; David W Threadgill; Ignacio I Wistuba; Jonathan M Kurie
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 7.  Targeting ADAMS and ERBBs in lung cancer.

Authors:  Nancy E Hynes; Thomas Schlange
Journal:  Cancer Cell       Date:  2006-07       Impact factor: 31.743

8.  IL-6 involvement in epithelial cancers.

Authors:  Zachary T Schafer; Joan S Brugge
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 9.  Evolution of protein kinase signaling from yeast to man.

Authors:  Gerard Manning; Gregory D Plowman; Tony Hunter; Sucha Sudarsanam
Journal:  Trends Biochem Sci       Date:  2002-10       Impact factor: 13.807

10.  DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers.

Authors:  W W Lockwood; R Chari; B P Coe; L Girard; C Macaulay; S Lam; A F Gazdar; J D Minna; W L Lam
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867
View more
  37 in total

1.  Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases.

Authors:  Albrecht Moritz; Yu Li; Ailan Guo; Judit Villén; Yi Wang; Joan MacNeill; Jon Kornhauser; Kam Sprott; Jing Zhou; Anthony Possemato; Jian Min Ren; Peter Hornbeck; Lewis C Cantley; Steven P Gygi; John Rush; Michael J Comb
Journal:  Sci Signal       Date:  2010-08-24       Impact factor: 8.192

2.  Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis.

Authors:  Hannah O'Farrell; Bryant Harbourne; Zimple Kurlawala; Yusuke Inoue; Amy L Nagelberg; Victor D Martinez; Daniel Lu; Min Hee Oh; Bradley P Coe; Kelsie L Thu; Romel Somwar; Stephen Lam; Wan L Lam; Arun M Unni; Levi Beverly; William W Lockwood
Journal:  J Thorac Oncol       Date:  2018-12-19       Impact factor: 15.609

3.  Colony stimulating factor-1 receptor promotes proliferation, migration and invasion in the human nasopharyngeal carcinoma 6-10B cell line via the phosphoinositide 3-kinase/Akt pathway.

Authors:  Jiayu Chen; Yanrong Hao; Jiaxin Chen; Li Huang; Wen Ao; Jiao Yang; Lei Li; Junping Heng; Zhaohon Chen; Wuqing Liang; Xin Hao; Weiwei Gao
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

4.  A targetable HB-EGF-CITED4 axis controls oncogenesis in lung cancer.

Authors:  C-H Hsieh; Y-T Chou; M-H Kuo; H-P Tsai; J-L Chang; C-W Wu
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

5.  Preneoplasia of lung cancer.

Authors:  Adi F Gazdar; Elisabeth Brambilla
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

6.  An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo.

Authors:  Koichi Tomoshige; Minzhe Guo; Tomoshi Tsuchiya; Takuya Fukazawa; Iris M Fink-Baldauf; William D Stuart; Yoshio Naomoto; Takeshi Nagayasu; Yutaka Maeda
Journal:  Oncogene       Date:  2018-04-17       Impact factor: 9.867

7.  Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Authors:  N Sunaga; K Kaira; H Imai; K Shimizu; T Nakano; D S Shames; L Girard; J Soh; M Sato; Y Iwasaki; T Ishizuka; A F Gazdar; J D Minna; M Mori
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

Review 8.  PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor.

Authors:  Ugur Hodoglugil; Michelle W Carrillo; Joan M Hebert; Niki Karachaliou; Rafael C Rosell; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-11       Impact factor: 2.089

9.  Pathogenesis of lung cancer signalling pathways: roadmap for therapies.

Authors:  E Brambilla; A Gazdar
Journal:  Eur Respir J       Date:  2009-06       Impact factor: 16.671

10.  Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.

Authors:  Junichi Soh; Naoki Okumura; William W Lockwood; Hiromasa Yamamoto; Hisayuki Shigematsu; Wei Zhang; Raj Chari; David S Shames; Ximing Tang; Calum MacAulay; Marileila Varella-Garcia; Tõnu Vooder; Ignacio I Wistuba; Stephen Lam; Rolf Brekken; Shinichi Toyooka; John D Minna; Wan L Lam; Adi F Gazdar
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.